Clinical trial transparency

Neurocrine recognizes that clinical research plays an important role in the education of healthcare professionals and in the advancement of patient health. All interventional clinical trials in patients are registered on Clinicaltrials.gov, EudraCT, and other relevant registry websites. Consistent with applicable laws and guidance, as well as the principles of transparency and disclosure, Neurocrine is committed to conveying clinical study research results in an objective, accurate, balanced, and complete manner that will include a discussion of the study's limitations. Results are disclosed regardless of whether they are positive or negative and are regularly shared with the scientific community through publication in peer-reviewed scientific and medical journals and congresses. In limited cases, Neurocrine may choose not to publish study results where the study was terminated before completion or where the results do not provide meaningful information about product safety or efficacy. However, we publish the available results of terminated interventional clinical trials that were conducted on patients in the clinical trial registry. We publish our results to clinical trial registries within a specific timeframe dictated by regional regulatory requirements.

Neurocrine fully supports openness and transparency. As such, all authors of publications (including Neurocrine Representatives and external collaborators) disclose any potential conflicts of interest, including financial or personal relationships that might be perceived to bias their work. Publications also contain an acknowledgement of the project's funding and Neurocrine's involvement in the analysis of data or preparation of the publication. Neurocrine accepts external requests for clinical trial data. Following approval of a new product or a new indication, Neurocrine will share protocols and anonymized patient-level or study-level data with qualified scientific and medical researchers on a case-by-case basis following review by an internal team.

Expanded Access to Investigational Medicines

While administration within the framework of controlled clinical research is optimal, there may be occasions when it is in the interest of some patients to have access to investigational medicines when enrollment in a clinical trial is not possible.

Where individuals have a serious or life-threatening disease or condition for which Neurocrine has a potential therapy and where all alternative treatment options, including enrolling in available clinical trials are not suitable, "expanded access" may be a suitable option. Neurocrine will carefully review all expanded access requests submitted by a physician or qualified Healthcare Professionals (HCPs) on a case-by-case basis and guided by our **Expanded Access to Investigational Medicines Policy**, which also includes the application submission directions for physicians or qualified HCPs.

Patient access and pricing

Patient access is a priority at Neurocrine Biosciences because discovering and developing new medicines alone is not enough. Important medical advancements can only change lives when they reach patients who need relief. We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, payers, and society. In doing so, we adhere to the highest ethical and compliance standards and are guided by the following principles:

- Improving the lives and wellbeing of patients
- Maximizing access and reducing out-of-pocket costs for eligible patients
- Striving to reduce obstacles for patients to fill a prescription or undergo treatment
- Fueling the discovery and development of life-changing medicines



Animal testing

We are committed to the ethical use of animals in biomedical research. All animal studies are carefully reviewed by an Institutional Animal Care and Use Committee (IACUC) which is charged with ensuring that a proposed study is essential. We comply with the "Three Rs" (Replace, Reduce and Refine), widely accepted ethical principles that are embedded in the conduct of animal-based science.